차바이오그룹은 차바이오텍, CMG제약, 차백신연구소 등 3개 상장사와 차헬스케어, 차메디텍, 차바이오F&C, 차케어스, 서울CRO, 솔리더스인베스트먼트 등으로 구성되어 있습니다. 국내 유일의 산·학·연·병(産·學·硏·病) 에코시스템과 Cell&Gene 기반의 R&D 역량을 바탕으로 세포∙ 유전자치료제와 차세대 백신을 비롯한 첨단바이오의약품을 개발하고 있습니다.
차바이오그룹은 마티카 바이오테크놀로지를 통해 3세대 세포∙유전자치료제 CDMO 사업을 본격화하고 있으며, LA 할리우드 차병원을 필두로 미국, 호주, 일본, 동남아시아에 직접 진출하며 K-의료한류를 선도하고 있습니다.
CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as Korea's only industry-university research ecosystem, the world's largest cell library, and our independently developed immune enhancement platform. We will leap forward as a true global bio company centered on the third-generation cell and gene therapy CDMO and global healthcare business.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://news.chabio.com/
차바이오그룹 Questions
차바이오그룹's website is https://news.chabio.com/
차바이오그룹's LinkedIn profile is https://www.linkedin.com/company/%EC%B0%A8%EB%B0%94%EC%9D%B4%EC%98%A4%EA%B7%B8%EB%A3%B9
차바이오그룹's industry is
Biotechnology Research
차바이오그룹's top competitors are
Cha Bio Group｜차바이오그룹,
Chabiotech,
Gravity Sketch,
Cha Health Systems, Inc.,
Ge Healthcare.
차바이오그룹's categories are Biotechnology Research
